Moderna Biotech UK Limited demonstrates a payment cycle centred in the 31-60 day band, which accounts for 61% of all payments, indicating a consistent mid-range settlement pattern rather than prompt payment behaviour. With only 16% of invoices paid within 30 days and an average payment time of 50 days, the company consistently operates beyond standard 30-day terms. The 23% of payments exceeding 60 days signals a recurring tail of delayed settlements that elevates the overall average.
Payment behaviour shows moderate predictability, with the majority of transactions falling within a defined 31-60 day window, suggesting an internal payment cycle of approximately 45-60 days rather than erratic processing. However, the 23% late payment rate — mirroring the over-60-day proportion — indicates a structural segment of invoices that consistently breach agreed terms, representing a reliable source of cash flow risk for suppliers. This dual-band pattern (concentrated mid-range with a persistent overdue tail) reduces overall payment reliability.
Suppliers should treat Moderna Biotech UK Limited as a moderate-to-elevated payment risk, factoring a realistic settlement window of 50+ days into cash flow planning rather than assuming standard 30-day terms will be honoured. The 23% late payment rate warrants proactive risk mitigation, including clearly defined payment terms in contracts, early payment incentives, and escalation procedures triggered at 45 days. Suppliers with tight liquidity constraints should consider requesting partial upfront payments or shorter contractual terms to offset the predictable delays.
| Reporting Period | Filing Date | Average Time to Pay (days) | Paid within 30 days | Paid 31-60 days | Paid after 60 days | Not Paid within Terms |
|---|---|---|---|---|---|---|
| 01 Jul 2025 - 31 Dec 2025 | 02 Feb 2026 | 50 | 16% | 61% | 23% | 23% |
| 01 Jan 2025 - 30 Jun 2025 | 30 Jul 2025 | 122 | 1% | 34% | 65% | 55% |
This information is as reported by the business, and responses are in their own words.
Standard payment terms
Net 60 for regular companies, Net 0 for healthcare professionals, government entities, insurance companies. These payment terms apply unless specifically stated in the agreement or the SOW.
Were there any changes to the standard payment terms in the reporting period?
No information available
Any other information about payment terms
No additional information
Maximum contractual payment period agreed
0
In case of unpaid invoice – supplier contacts accountspayable@modernatx.com who is responsible for payment terms verification and preparing payment as soon as possible In case of quality/quantity/price difference – invoice is rejected back to supplier’s contact address by Accounts Payable based on order owner’s comment with a standard notification (wording may be slightly different depending on rejection reason): Dear Supplier, please be informed that your invoice has been rejected by order owner due to quality/quantity/price difference. Please contact your Moderna Business Contact to explain the difference. Amended invoice please resubmit to invoice@modernatx.com. Thank you for your understanding. Kind Regards, Moderna Accounts Payable Team
Has this business signed up to a code of conduct or standards on payment practices?
For example, signatories to The Prompt Payment Code must commit to paying 95% of their invoices within 60 days.
❌
Does this business offer e-invoicing in relation to qualifying contracts?
This is where suppliers can electronically submit and track invoices. It's not just allowing suppliers to email them an invoice.
❌
Does this business offer supply chain finance?
This is where a supplier who has submitted an invoice can be paid by a third-party finance provider earlier than the agreed payment date. The business would then pay the finance provider the invoiced sum.
❌
Under its payment practices and policies, can this business deduct sums from payments under qualifying contracts as a charge for remaining on a supplier list?
❌
During the reporting period, did the business deduct sums from payments as a charge for remaining on a supplier list?
No information available
Moderna Biotech UK Limited is a private limited company operating within the biotechnology sector in the United Kingdom. As part of the globally recognised Moderna organisation, the company represents the British presence of one of the world's leading biotechnology enterprises.
The company was incorporated on 10 May 2019 and holds company registration number 11990046 with Companies House. Its registered office is located at 54 Portland Place, London, England, W1B 1DY, placing it at the heart of one of the United Kingdom's most prominent business and professional districts.
Biotechnology companies of this nature operating in the UK market are typically engaged in the research, development, and commercialisation of innovative medical and scientific solutions. This includes activities such as the development of therapeutic treatments, vaccines, and other biological medicines, as well as regulatory engagement with UK health authorities and collaboration with the broader life sciences sector.
With its Active status confirmed by Companies House, Moderna Biotech UK Limited continues to maintain its registered presence in the United Kingdom, contributing to the country's growing life sciences and biotechnology industry.